

CELGENE CORP /DE/  
Form 4  
July 29, 2015

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Daniel Thomas O

(Last) (First) (Middle)

C/O CELGENE CORPORATION, 86 MORRIS AVENUE

(Street)

SUMMIT, NJ 07901

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
CELGENE CORP /DE/ [CELG]

3. Date of Earliest Transaction (Month/Day/Year)  
07/27/2015

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
see remarks

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount or Price		
Common Stock	07/28/2015		M		1,720 A \$ 28.94	57,252	D
Common Stock	07/28/2015		M		13,000 A \$ 29.75	70,252	D
Common Stock	07/28/2015		M		15,000 A \$ 29.75	85,252	D
Common Stock	07/28/2015		S		29,720 D \$ 133.96	55,532	D
	07/28/2015		M		2,292 A \$ 28.5	57,824	D

Common Stock									
Common Stock	07/28/2015		M	1,506	A	\$ 36.96	59,330		D
Common Stock	07/28/2015		M	1,720	A	\$ 25.77	61,050		D
Common Stock	07/28/2015		M	1,128	A	\$ 30.74	62,178		D
Common Stock							3,200	I	401(k) Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares
Stock Option (right to buy)	\$ 132.56	07/27/2015		A	8,625	(2) 07/27/2025	Common Stock 8,625
Stock Option (right to buy)	\$ 28.94	07/28/2015		M	1,720	(4) 10/12/2020	Common Stock 1,720
Stock Option (right to buy)	\$ 29.75	07/28/2015		M	13,000	(4) 12/27/2020	Common Stock 13,000
Stock Option (right to buy)	\$ 29.75	07/28/2015		M	15,000	(4) 12/27/2020	Common Stock 15,000
	\$ 28.5	07/28/2015		M	2,292	(4) 01/12/2020	2,292

Stock Option (right to buy)								Common Stock	
Stock Option (right to buy)	\$ 36.96	07/28/2015	M	1,506	(4)	03/01/2022	Common Stock	1,506	
Stock Option (right to buy)	\$ 25.77	07/28/2015	M	1,720	(4)	01/31/2021	Common Stock	1,720	
Stock Option (right to buy)	\$ 30.74	07/28/2015	M	1,128	(4)	04/13/2020	Common Stock	1,128	

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Daniel Thomas O C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT, NJ 07901			see remarks	

## Signatures

/s/ Robert J. Hugin

Robert J. Hugin, Attorney-in-Fact 07/29/2015

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person pursuant to a Rule 10b5-1 plan in multiple transactions at prices ranging from \$132.75 to \$135.49, inclusive. The reporting person undertakes to provide Celgene

- (1) Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- (2) Option is immediately exercisable and will vest in four equal annual installments commencing on July 27, 2016.
- (3) The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015).
- (4) The option was fully exercisable.

### Remarks:

President, Research and Early Development

## Edgar Filing: CELGENE CORP /DE/ - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.  
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.